EP4171533A1 - A film coated tablet comprising vildagliptin and metformin hci - Google Patents

A film coated tablet comprising vildagliptin and metformin hci

Info

Publication number
EP4171533A1
EP4171533A1 EP21829623.4A EP21829623A EP4171533A1 EP 4171533 A1 EP4171533 A1 EP 4171533A1 EP 21829623 A EP21829623 A EP 21829623A EP 4171533 A1 EP4171533 A1 EP 4171533A1
Authority
EP
European Patent Office
Prior art keywords
sodium
vildagliptin
tablet according
mixtures
mixture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP21829623.4A
Other languages
German (de)
French (fr)
Other versions
EP4171533A4 (en
Inventor
Vildan TOMBAYOGLU
Arzu PALANTOKEN
Fatih Sunel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanovel Ilac Sanayi ve Ticaret AS
Original Assignee
Sanovel Ilac Sanayi ve Ticaret AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanovel Ilac Sanayi ve Ticaret AS filed Critical Sanovel Ilac Sanayi ve Ticaret AS
Publication of EP4171533A1 publication Critical patent/EP4171533A1/en
Publication of EP4171533A4 publication Critical patent/EP4171533A4/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil

Definitions

  • the present invention relates to a film coated tablet comprising vildagliptin/vildagliptin HCI and metformin HCI and at least one pharmaceutically acceptable excipient.
  • the present invention also relates to a simple, rapid, cost effective, time-saving and industrially convenient process.
  • Diabetes mellitus is a group of disorders of carbohydrate metabolism in which the action of insulin is diminished or absent through altered secretion, decreased insulin activity or a combination of both factors.
  • Type 1 and Type 2 There are two main types of diabetes; Type 1 and Type 2:
  • Type 1 diabetes occurs because the insulin-producing cells of the pancreas (beta cells) are damaged. In Type 1 diabetes, the pancreas makes little or no insulin, so sugar cannot get into the body's cells for use as energy. People with Type 1 diabetes must use insulin injections to control their blood glucose.
  • Type 2 diabetes the pancreas makes insulin, but it either doesn't produce enough, or the insulin does not work properly. This diabetes occurs most often in people who are over 40 years old and overweight. Type 2 diabetes may sometimes be controlled with a combination of diet, weight management, and exercise. However, treatment also may include oral glucose-lowering medications or insulin injections.
  • Vildagliptin is a dipeptidyl dipeptidase-IV (DPP-IV) inhibitor developed for use in the treatment of type 2 diabetes (non-insulin dependent diabetes).
  • DPP-IV dipeptidyl dipeptidase-IV
  • vildagliptin inhibits the degradation of the dipeptidyl dipeptidase-IV enzyme, thereby inhibiting the effects of incretin hormones, glucagon-like peptide-1 (GLP-1), and of glucose-dependent insulinotropic peptide (GIP).
  • GLP-1 glucagon-like peptide-1
  • GIP glucose-dependent insulinotropic peptide
  • the chemical designation of vildagliptin is (S)- ⁇ [(3-hydroxyadamantan-1- yl)amino]acetyl ⁇ pyrrolidine-2-carbonitrile, with the chemical structure illustrated below in Formula 1.
  • Vildagliptin is soluble in water and in organic polar solvents.
  • Vildagliptin is marketed under the trademark Galvus ® in 50 mg dosage forms. It is used against diabetes mellitus, but particularly in treating type 2 diabetes.
  • Metformin is antidiabetics having an orally-administrated biguanide structure.
  • Metformin hydrochloride is a white to off-white crystalline compound and it is freely soluble in water and practically insoluble in acetone, ether and chloroform.
  • Oral doses of metformin are generally recommended in the range of 500 to 2500 mg a day and a single dose may vary from 500 to 850 mg. It is used singly or in combination with sulfonylureas, alpha-glucosidase inhibitors, or insulin.
  • metformin hydrochloride is 1 ,1 -dimethylbiguanide hydrochloride, has the following chemical structure of Formula II.
  • Combination product of vildagliptin and metformin hydrochloride is marketed under the trademark Eucreas® (50mg/850mg and 50mg/1000mg dosage forms of vildagliptin and metformin hydrochloride).
  • Pharmaceutical formulations of combined respective active ingredients and the process for their preparation are disclosed in EP 1948149.
  • Combination preparations of metformin and vildagliptin are described in WO 2007/041053.
  • a tablet disclosed can contain, in addition to the active substances, usual excipients, for example fillers, binders, disintegrants, lubricants and colorants.
  • lubricants examples include colloidal silica, magnesium trisilicate, starch, talc, calcium phosphate, magnesium stearate, aluminium stearate, calcium stearate, magnesium carbonate, magnesium oxide, polyethylene glycol, cellulose and microcrystalline cellulose.
  • EP2477660 (A1) discloses a pharmaceutical composition
  • a pharmaceutical composition comprising an active agent metformin or its salt in combination with an active agent sitagliptin or vildagliptin or their salt, and a lubricant (more than 10 wt.%, based on the total weight of the composition).
  • the lubricant is polyethylene glycol or a mixture of polyethylene glycol with at least one of the other lubricant.
  • vildagliptin Both metformin HCI and vildagliptin have some structural problems. Stability-related problems do occur in many active agents, including vildagliptin, under the influence of ambient and physical conditions.
  • Vildagliptin is an active agent that is highly-susceptible to air and humidity. When vildagliptin is exposed to air and humidity, it degrades structurally and develops chemical behavioral changes. The stability of vildagliptin products developed is not at a desired level and the shelf life thereof is shortened.
  • vildagliptin is reactive against the excipients employed in developing formulations containing the same. This fact causes impurities to occur in the formulation and leads to the inclusion of undesired components into the formulation. Also, the compressibility of metformin is poor. Considering these, it is very difficult to create a formulation comprising vildagliptin and metformin HCI.
  • vildagliptin or vildagliptin HCI and a mixture comprising metformin HCI was prepared.
  • a tablet formulation was created to overcome the above problems with a certain proportion and selected excipients.
  • the main object of the present invention is to provides a tablet comprising vildagliptin/vildagliptin HCI and metformin HCI capable of being compressed into a tablet having adequate size, hardness, rapid disintegration time and an acceptable dissolution profile.
  • Another object of the present invention is to provide a tablet, considering the negative structural features of metformin HCI and vildagliptin, having effective treatment and high stability formulation and an effective process.
  • a tablet comprises;
  • the ratio of the mixture comprising metformin hydrochloride ( %95 DC, metformin granulate Direct Compressible grade %95) to vildagliptin or vildagliptin HCI is in the range of 15:1 to 22:1 , preferably 16:1 to 21 :1 by weight. The ratio helps to provide the desired dissolution profile and the desired stability.
  • the amount of vildagliptin or vildagliptin HCI is between 1.0% and 10.0% by weight in the total formulation. Preferably, it is between 2.0% and 7.0% or 3.0% and 5.0% by weight in the total formulation.
  • the amount of a mixture comprising metformin hydrochloride is between 60.0% and 87.0% by weight in the total formulation. Preferably, it is between 67.0% and 85.0% or 74.0% and 82.0% by weight in the total formulation.
  • the amount of metformin hydrochloride is between 92.0% and 97.0% by weight in the mixture. Preferably, it is 95.0% by weight in the mixture.
  • Metformin HCI is used big proportion that can lead to considerable problems during the preparation of formulation with regard to the uniformity of the content of active agent in the individual composition units. Because of problems uniformity of the content, the active substance may interact with several excipients. It reflects that content uniformity play important role in the dissolution of the drug. Also, in terms of physical properties, the compressibility of metformin is poor, and how to obtain a tablet or a capsule having an acceptable mechanical strength is an important problem in formulation development.
  • a mixture comprising metformin HCI was prepared. So, it helps to provide the desired uniformity of the content and therefore it provides the desired dissolution profile. Also, the mixture ensures the desired compressibility and high physically. Thanks to the mixture comprising metformin HCI %95.0 DC, compressing of tablet can made by direct compression without extra process even if metformin had low compressibility.
  • the mixture comprising metformin HCI %95 DC also comprises at least one pharmaceutically acceptable excipient.
  • the excipients are selected from the group comprising fillers, binders, lubricants or mixtures thereof.
  • a tablet comprises at least one pharmaceutically acceptable excipient which is selected from the group comprising binders, fillers, disintegrants, lubricants, glidants, moisture absorbing agents, coating agents or mixtures.
  • excipients provided in a formulation may positively or negatively influence the physicochemical and pharmacokinetic properties, e.g. the solubility, absorption, bioavailability of an active agent. For this reason, the excipients which accompany an active agent have to be selected in a careful and conscious manner while a formulation is developed.
  • the formulations should have no physicochemical incompatibility between the active agents and the excipients.
  • Suitable fillers are selected from the group comprising microcrystalline cellulose, mannitol, spray-dried mannitol, lactose, lactose monohydrate, starch, dextrose, sucrose, fructose, maltose, sorbitol, xylitol, inositol, kaolin, inorganic salts, calcium salts, polysaccharides, dicalcium phosphate, sodium chloride, dextrates, lactitol, maltodextrin, sucrose-maltodextrin mixture, trehalose, sodium carbonate, sodium bicarbonate, calcium carbonate or mixtures thereof.
  • the amount of fillers is between 3.0% and 20.0% by weight in the total formulation. Preferably, it is between 4.0% and 10.0% or 10.0% and 20.0% or 10.0% and 16.0% by weight in the total formulation.
  • the filler is microcrystalline cellulose or mannitol or mixtures thereof.
  • Suitable binders are selected from the group comprising copovidone sodium carboxymethyl cellulose, crospovidone, polyethylene glycol, polyvinyl alcohol, starch, pregelatinized starch, glucose, glucose syrup, natural gums, sucrose, sodium alginate, hydroxypropyl methyl cellulose, hydroxypropyl cellulose, carboxy methyl cellulose, methyl cellulose, gelatin, carrageenan, guar gum, carbomer, polymethacrylates, methacrylate polymers, gelatin, agar, alginate, alginic acid, xanthan gum, hyaluronic acid, pectin, polysaccharides, carbomer, poloxamer, polyacrylamide, aluminium hydroxide, laponit, bentonit, polyoxyethylene-alkyl ether, polydextrose, polyethylene oxide or mixtures thereof.
  • the amount of binders is between 0.01% and 10.0% by weight in the total formulation.
  • the binder is copovidone.
  • Suitable disintegrants are selected from the group comprising croscarmellose sodium, low- substituted hydroxypropyl cellulose, pregelatinized starch, sodium carboxymethyl cellulose, calcium carboxymethyl cellulose, carboxymethyl cellulose, docusate sodium, guar gum, low substituted hydroxypropyl cellulose, polyacryline potassium, sodium alginate, corn starch, sodium starch glycolate, alginic acid, alginates, ion-exchange resins, magnesium aluminium silica, sodium dodecyl sulphate, poloxamer, sodium glycine carbonate, sodium lauryl sulphate or mixtures thereof.
  • the amount of disintegrants is between 0.1% and 5.0% by weight in the total formulation.
  • the disintegrant is croscarmellose sodium.
  • Suitable lubricants are selected from the group comprising from magnesium stearate, colloidal silicon dioxide, calcium stearate, zinc stearate, waxes, boric acid, hydrogenated vegetable oil, sodium chlorate, magnesium lauryl sulfate, sodium oleate, sodium acetate, sodium benzoate, stearic acid, fatty acid, fumaric acid, glyceryl palmito sulphate, sodium stearyl fumarate, sodium lauryl sulphate or mixtures thereof.
  • the amount of lubricants is between 0.01% and 3.0% by weight in the total formulation.
  • the lubricant is magnesium stearate.
  • Suitable glidants are selected from the group comprising talc, colloidal silicon dioxide, corn starch or mixtures thereof.
  • the amount of glidants is between 0.01% and 3.0% by weight in the total formulation.
  • the glidant is talc.
  • Suitable moisture absorbing agents are selected from the group comprising calcium chloride, calcium sulfate, activated carbon, zeolites, silica gel or mixtures thereof. According to one embodiment of the present invention, the amount of moisture absorbing agents is between 0.001% and 1 .0% by weight in the total formulation.
  • the moisture absorbing agent is calcium chloride. Also, it helps to provide the desired dissolution profile.
  • Suitable coating agents are selected from the group comprising copovidone, polymethacrylates, polydextrose, polyalkylacrylates copolymers, triacetin, hydroxyl propyl methyl cellulose, colloidal silicon dioxide, lactose monohydrate, medium chain triglycerides, hydroxypropyl cellulose, white wax, polyvinyl alcohol, polyethylene glycol, talc, polyvinyl alcohol-polyethylene glycol copolymers (Kollicoat® IR), ethylcellulose dispersions (Surelease®), polyvinylprolidone, polyvinylprolidone-vinyl acetate copolymer (PVP-VA), all kinds of Opadry®, pigments, dyes, titanium dioxide, iron oxide or mixtures thereof.
  • the amount of coating comprising coating agents is between 0.5% and 5.0% by weight in the total formulation. Preferably, it is between 1.5% and 3.5% by weight in the total formulation.
  • the mixture comprising metformin HCI %95 DC also comprises at least one pharmaceutically acceptable excipient.
  • the excipients are selected from the group comprising microcrystalline cellulose, sodium carboxymethyl cellulose, polyvinylpyrrolidone (K30, K90), magnesium stearate, pregelatinized starch, crospovidone or mixtures thereof.
  • the mixture comprising metformin HCI %95 DC also comprises microcrystalline cellulose and polyvinylpyrrolidone (K30, K90). Surprisingly, this provides the desired content homogeneity of metformin HCI, so it ensures the desired dissolution profile in the tablet.
  • the tablet comprising copovidone, microcrystalline cellulose, mannitol, magnesium stearate, talc, calcium chloride, croscarmellose sodium or mixtures thereof.
  • the tablet of the present invention may be prepared, using standard techniques and manufacturing processes well known in the art, such as direct compression, wet or dry granulation, hot melt granulation, hot melt extrusion, fluidized bed granulation, extrusion/spheronization, slugging, spray drying and solvent evaporation.
  • the tablet is obtained by using direct compression, it is a simple and low-cost production method was employed. Also, since vildagliptin is highly-susceptible to air and humidity, this method is advantage because it does not contain high humidity environment and it is fast.
  • Example 1 The tablet formulation comprising vildagliptin and metformin HCI
  • Example 2 The tablet formulation comprising vildagliptin and metformin HCI
  • Example 3 The tablet formulation comprising vildagliptin and metformin HCI
  • Example 4 The tablet formulation comprising vildagliptin and metformin HCI
  • Example 5 The tablet formulation comprising vildagliptin and metformin HCI
  • Example 6 The tablet formulation comprising vildagliptin and metformin HCI
  • Example 7 The tablet formulation comprising vildagliptin and metformin HCI
  • Example 8 The tablet formulation comprising vildagliptin and metformin HCI Process for the described above tablet formulation examples;
  • Example 9 A mixture comprising metformin HCI %95 DC q.s: Quantity sufficient
  • Example 10 A mixture comprising metformin HCI %95 DC q.s: Quantity sufficient
  • Example 11 A mixture comprising metformin HCI %95 DC
  • Example 12 A mixture comprising metformin HCI %95 DC

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

The present invention relates to a film coated tablet comprising vildagliptin/vildagliptin HCI and metformin HCI and at least one pharmaceutically acceptable excipient. The present invention also relates to a simple, rapid, cost effective, time-saving and industrially convenient process.

Description

A FILM COATED TABLET COMPRISING VILDAGLIPTIN AND METFORMIN HCI Field of the Invention
The present invention relates to a film coated tablet comprising vildagliptin/vildagliptin HCI and metformin HCI and at least one pharmaceutically acceptable excipient. The present invention also relates to a simple, rapid, cost effective, time-saving and industrially convenient process.
Background of the Invention
Diabetes mellitus is a group of disorders of carbohydrate metabolism in which the action of insulin is diminished or absent through altered secretion, decreased insulin activity or a combination of both factors. There are two main types of diabetes; Type 1 and Type 2:
Type 1 diabetes occurs because the insulin-producing cells of the pancreas (beta cells) are damaged. In Type 1 diabetes, the pancreas makes little or no insulin, so sugar cannot get into the body's cells for use as energy. People with Type 1 diabetes must use insulin injections to control their blood glucose.
In Type 2 diabetes, the pancreas makes insulin, but it either doesn't produce enough, or the insulin does not work properly. This diabetes occurs most often in people who are over 40 years old and overweight. Type 2 diabetes may sometimes be controlled with a combination of diet, weight management, and exercise. However, treatment also may include oral glucose-lowering medications or insulin injections.
Vildagliptin is a dipeptidyl dipeptidase-IV (DPP-IV) inhibitor developed for use in the treatment of type 2 diabetes (non-insulin dependent diabetes). Vildagliptin inhibits the degradation of the dipeptidyl dipeptidase-IV enzyme, thereby inhibiting the effects of incretin hormones, glucagon-like peptide-1 (GLP-1), and of glucose-dependent insulinotropic peptide (GIP). The chemical designation of vildagliptin is (S)-{[(3-hydroxyadamantan-1- yl)amino]acetyl}pyrrolidine-2-carbonitrile, with the chemical structure illustrated below in Formula 1.
Formula 1
Vildagliptin is soluble in water and in organic polar solvents.
Vildagliptin is marketed under the trademark Galvus® in 50 mg dosage forms. It is used against diabetes mellitus, but particularly in treating type 2 diabetes.
Metformin is antidiabetics having an orally-administrated biguanide structure. Metformin hydrochloride is a white to off-white crystalline compound and it is freely soluble in water and practically insoluble in acetone, ether and chloroform. Oral doses of metformin are generally recommended in the range of 500 to 2500 mg a day and a single dose may vary from 500 to 850 mg. It is used singly or in combination with sulfonylureas, alpha-glucosidase inhibitors, or insulin.
The chemical name of metformin hydrochloride is 1 ,1 -dimethylbiguanide hydrochloride, has the following chemical structure of Formula II.
Combination product of vildagliptin and metformin hydrochloride is marketed under the trademark Eucreas® (50mg/850mg and 50mg/1000mg dosage forms of vildagliptin and metformin hydrochloride). Pharmaceutical formulations of combined respective active ingredients and the process for their preparation are disclosed in EP 1948149. Combination preparations of metformin and vildagliptin are described in WO 2007/041053. A tablet disclosed can contain, in addition to the active substances, usual excipients, for example fillers, binders, disintegrants, lubricants and colorants. Examples of lubricants that are mentioned are colloidal silica, magnesium trisilicate, starch, talc, calcium phosphate, magnesium stearate, aluminium stearate, calcium stearate, magnesium carbonate, magnesium oxide, polyethylene glycol, cellulose and microcrystalline cellulose.
EP2477660 (A1) discloses a pharmaceutical composition comprising an active agent metformin or its salt in combination with an active agent sitagliptin or vildagliptin or their salt, and a lubricant (more than 10 wt.%, based on the total weight of the composition). The lubricant is polyethylene glycol or a mixture of polyethylene glycol with at least one of the other lubricant.
Both metformin HCI and vildagliptin have some structural problems. Stability-related problems do occur in many active agents, including vildagliptin, under the influence of ambient and physical conditions. Vildagliptin is an active agent that is highly-susceptible to air and humidity. When vildagliptin is exposed to air and humidity, it degrades structurally and develops chemical behavioral changes. The stability of vildagliptin products developed is not at a desired level and the shelf life thereof is shortened. In addition, vildagliptin is reactive against the excipients employed in developing formulations containing the same. This fact causes impurities to occur in the formulation and leads to the inclusion of undesired components into the formulation. Also, the compressibility of metformin is poor. Considering these, it is very difficult to create a formulation comprising vildagliptin and metformin HCI.
In the present invention, vildagliptin or vildagliptin HCI and a mixture comprising metformin HCI was prepared. A tablet formulation was created to overcome the above problems with a certain proportion and selected excipients.
Detailed Description of the Invention
The main object of the present invention is to provides a tablet comprising vildagliptin/vildagliptin HCI and metformin HCI capable of being compressed into a tablet having adequate size, hardness, rapid disintegration time and an acceptable dissolution profile.
Another object of the present invention is to provide a tablet, considering the negative structural features of metformin HCI and vildagliptin, having effective treatment and high stability formulation and an effective process. According to one embodiment of the invention, a tablet comprises;
- Vildagliptin or vildagliptin HCI
A mixture comprising metformin hydrochloride
- At least one pharmaceutically acceptable excipient
Wherein the ratio of the mixture comprising metformin hydrochloride ( %95 DC, metformin granulate Direct Compressible grade %95) to vildagliptin or vildagliptin HCI is in the range of 15:1 to 22:1 , preferably 16:1 to 21 :1 by weight. The ratio helps to provide the desired dissolution profile and the desired stability.
According to one embodiment of the present invention, the amount of vildagliptin or vildagliptin HCI is between 1.0% and 10.0% by weight in the total formulation. Preferably, it is between 2.0% and 7.0% or 3.0% and 5.0% by weight in the total formulation.
According to one embodiment of the present invention, the amount of a mixture comprising metformin hydrochloride is between 60.0% and 87.0% by weight in the total formulation. Preferably, it is between 67.0% and 85.0% or 74.0% and 82.0% by weight in the total formulation.
According to one embodiment of the present invention, the amount of metformin hydrochloride is between 92.0% and 97.0% by weight in the mixture. Preferably, it is 95.0% by weight in the mixture.
Metformin HCI is used big proportion that can lead to considerable problems during the preparation of formulation with regard to the uniformity of the content of active agent in the individual composition units. Because of problems uniformity of the content, the active substance may interact with several excipients. It reflects that content uniformity play important role in the dissolution of the drug. Also, in terms of physical properties, the compressibility of metformin is poor, and how to obtain a tablet or a capsule having an acceptable mechanical strength is an important problem in formulation development.
In the present invention, a mixture comprising metformin HCI was prepared. So, it helps to provide the desired uniformity of the content and therefore it provides the desired dissolution profile. Also, the mixture ensures the desired compressibility and high physically. Thanks to the mixture comprising metformin HCI %95.0 DC, compressing of tablet can made by direct compression without extra process even if metformin had low compressibility.
According to one embodiment of the present invention, the mixture comprising metformin HCI %95 DC also comprises at least one pharmaceutically acceptable excipient. The excipients are selected from the group comprising fillers, binders, lubricants or mixtures thereof.
According to one embodiment of the invention, a tablet comprises at least one pharmaceutically acceptable excipient which is selected from the group comprising binders, fillers, disintegrants, lubricants, glidants, moisture absorbing agents, coating agents or mixtures.
In general terms, excipients provided in a formulation may positively or negatively influence the physicochemical and pharmacokinetic properties, e.g. the solubility, absorption, bioavailability of an active agent. For this reason, the excipients which accompany an active agent have to be selected in a careful and conscious manner while a formulation is developed. The formulations should have no physicochemical incompatibility between the active agents and the excipients.
Suitable fillers are selected from the group comprising microcrystalline cellulose, mannitol, spray-dried mannitol, lactose, lactose monohydrate, starch, dextrose, sucrose, fructose, maltose, sorbitol, xylitol, inositol, kaolin, inorganic salts, calcium salts, polysaccharides, dicalcium phosphate, sodium chloride, dextrates, lactitol, maltodextrin, sucrose-maltodextrin mixture, trehalose, sodium carbonate, sodium bicarbonate, calcium carbonate or mixtures thereof.
According to one embodiment of the present invention, the amount of fillers is between 3.0% and 20.0% by weight in the total formulation. Preferably, it is between 4.0% and 10.0% or 10.0% and 20.0% or 10.0% and 16.0% by weight in the total formulation.
According to one embodiment of the present invention, the filler is microcrystalline cellulose or mannitol or mixtures thereof.
Suitable binders are selected from the group comprising copovidone sodium carboxymethyl cellulose, crospovidone, polyethylene glycol, polyvinyl alcohol, starch, pregelatinized starch, glucose, glucose syrup, natural gums, sucrose, sodium alginate, hydroxypropyl methyl cellulose, hydroxypropyl cellulose, carboxy methyl cellulose, methyl cellulose, gelatin, carrageenan, guar gum, carbomer, polymethacrylates, methacrylate polymers, gelatin, agar, alginate, alginic acid, xanthan gum, hyaluronic acid, pectin, polysaccharides, carbomer, poloxamer, polyacrylamide, aluminium hydroxide, laponit, bentonit, polyoxyethylene-alkyl ether, polydextrose, polyethylene oxide or mixtures thereof. According to one embodiment of the present invention, the amount of binders is between 0.01% and 10.0% by weight in the total formulation.
According to one embodiment of the present invention, the binder is copovidone.
Suitable disintegrants are selected from the group comprising croscarmellose sodium, low- substituted hydroxypropyl cellulose, pregelatinized starch, sodium carboxymethyl cellulose, calcium carboxymethyl cellulose, carboxymethyl cellulose, docusate sodium, guar gum, low substituted hydroxypropyl cellulose, polyacryline potassium, sodium alginate, corn starch, sodium starch glycolate, alginic acid, alginates, ion-exchange resins, magnesium aluminium silica, sodium dodecyl sulphate, poloxamer, sodium glycine carbonate, sodium lauryl sulphate or mixtures thereof.
According to one embodiment of the present invention, the amount of disintegrants is between 0.1% and 5.0% by weight in the total formulation.
According to one embodiment of the present invention, the disintegrant is croscarmellose sodium.
Suitable lubricants are selected from the group comprising from magnesium stearate, colloidal silicon dioxide, calcium stearate, zinc stearate, waxes, boric acid, hydrogenated vegetable oil, sodium chlorate, magnesium lauryl sulfate, sodium oleate, sodium acetate, sodium benzoate, stearic acid, fatty acid, fumaric acid, glyceryl palmito sulphate, sodium stearyl fumarate, sodium lauryl sulphate or mixtures thereof.
According to one embodiment of the present invention, the amount of lubricants is between 0.01% and 3.0% by weight in the total formulation.
According to one embodiment of the present invention, the lubricant is magnesium stearate.
Suitable glidants are selected from the group comprising talc, colloidal silicon dioxide, corn starch or mixtures thereof.
According to one embodiment of the present invention, the amount of glidants is between 0.01% and 3.0% by weight in the total formulation.
According to one embodiment of the present invention, the glidant is talc.
Suitable moisture absorbing agents are selected from the group comprising calcium chloride, calcium sulfate, activated carbon, zeolites, silica gel or mixtures thereof. According to one embodiment of the present invention, the amount of moisture absorbing agents is between 0.001% and 1 .0% by weight in the total formulation.
According to one embodiment of the present invention, the moisture absorbing agent is calcium chloride. Also, it helps to provide the desired dissolution profile.
Suitable coating agents are selected from the group comprising copovidone, polymethacrylates, polydextrose, polyalkylacrylates copolymers, triacetin, hydroxyl propyl methyl cellulose, colloidal silicon dioxide, lactose monohydrate, medium chain triglycerides, hydroxypropyl cellulose, white wax, polyvinyl alcohol, polyethylene glycol, talc, polyvinyl alcohol-polyethylene glycol copolymers (Kollicoat® IR), ethylcellulose dispersions (Surelease®), polyvinylprolidone, polyvinylprolidone-vinyl acetate copolymer (PVP-VA), all kinds of Opadry®, pigments, dyes, titanium dioxide, iron oxide or mixtures thereof.
According to one embodiment of the present invention, the amount of coating comprising coating agents is between 0.5% and 5.0% by weight in the total formulation. Preferably, it is between 1.5% and 3.5% by weight in the total formulation.
According to one embodiment of the present invention, the mixture comprising metformin HCI %95 DC also comprises at least one pharmaceutically acceptable excipient. The excipients are selected from the group comprising microcrystalline cellulose, sodium carboxymethyl cellulose, polyvinylpyrrolidone (K30, K90), magnesium stearate, pregelatinized starch, crospovidone or mixtures thereof.
According to one embodiment of the present invention, the mixture comprising metformin HCI %95 DC also comprises microcrystalline cellulose and polyvinylpyrrolidone (K30, K90). Surprisingly, this provides the desired content homogeneity of metformin HCI, so it ensures the desired dissolution profile in the tablet.
According to one embodiment of the present invention, the tablet comprising copovidone, microcrystalline cellulose, mannitol, magnesium stearate, talc, calcium chloride, croscarmellose sodium or mixtures thereof.
The tablet of the present invention may be prepared, using standard techniques and manufacturing processes well known in the art, such as direct compression, wet or dry granulation, hot melt granulation, hot melt extrusion, fluidized bed granulation, extrusion/spheronization, slugging, spray drying and solvent evaporation.
According to one embodiment of the present invention, the tablet is obtained by using direct compression, it is a simple and low-cost production method was employed. Also, since vildagliptin is highly-susceptible to air and humidity, this method is advantage because it does not contain high humidity environment and it is fast.
Example 1 : The tablet formulation comprising vildagliptin and metformin HCI
Example 2: The tablet formulation comprising vildagliptin and metformin HCI Example 3: The tablet formulation comprising vildagliptin and metformin HCI
Example 4: The tablet formulation comprising vildagliptin and metformin HCI Example 5: The tablet formulation comprising vildagliptin and metformin HCI
Example 6: The tablet formulation comprising vildagliptin and metformin HCI Example 7: The tablet formulation comprising vildagliptin and metformin HCI
Example 8: The tablet formulation comprising vildagliptin and metformin HCI Process for the described above tablet formulation examples;
Mixing the mixture comprising metformin HCI and all ingredients in the tables except for magnesium stearate and coating agents,
- Adding magnesium stearate and mixing,
- Compressing to form of a tablet,
- Coating tablets with coating agents,
Example 9: A mixture comprising metformin HCI %95 DC q.s: Quantity sufficient
Example 10: A mixture comprising metformin HCI %95 DC q.s: Quantity sufficient
Example 11 : A mixture comprising metformin HCI %95 DC Example 12: A mixture comprising metformin HCI %95 DC
Example 13: Coating
Example 14: Coating

Claims

1. A tablet comprising;
- Vildagliptin or vildagliptin HCI
A mixture comprising metformin hydrochloride
- At least one pharmaceutically acceptable excipient
Wherein the ratio of the mixture comprising metformin hydrochloride to vildagliptin or vildagliptin HCI is in the range of 15:1 to 22:1 , preferably 16:1 to 21 :1 by weight.
2. The tablet according to claim 1 , wherein the amount of vildagliptin or vildagliptin HCI is between 1.0% and 10.0% by weight in the total formulation.
3. The tablet according to claim 1 , wherein the amount of a mixture comprising metformin hydrochloride is between 60.0% and 87.0% by weight in the total formulation.
4. The tablet according to claim 1 , wherein the amount of metformin hydrochloride is between 92.0% and 97.0% by weight in the mixture.
5. The tablet according to claim 1 , wherein the mixture comprising metformin HCI comprising at least one pharmaceutically acceptable excipient which are selected from the group comprising fillers, binders, lubricants or mixtures thereof.
6. The tablet according to claim 1 , wherein the tablet comprising at least one pharmaceutically acceptable excipient which is selected from the group comprising binders, fillers, disintegrants, lubricants, glidants, moisture absorbing agents, coating agents or mixtures.
7. The tablet according to claim 5 or 6, wherein fillers are selected from the group comprising microcrystalline cellulose, mannitol, spray-dried mannitol, lactose, lactose monohydrate, starch, dextrose, sucrose, fructose, maltose, sorbitol, xylitol, inositol, kaolin, inorganic salts, calcium salts, polysaccharides, dicalcium phosphate, sodium chloride, dextrates, lactitol, maltodextrin, sucrose-maltodextrin mixture, trehalose, sodium carbonate, sodium bicarbonate, calcium carbonate or mixtures thereof.
8. The tablet according to claim 5 or 6, wherein binders are selected from the group comprising copovidone sodium carboxymethyl cellulose, polyethylene glycol, polyvinyl alcohol, starch, pregelatinized starch, glucose, glucose syrup, natural gums, sucrose, sodium alginate, hydroxypropyl methyl cellulose, hydroxypropyl cellulose, carboxy methyl cellulose, methyl cellulose, gelatin, carrageenan, guar gum, carbomer, polymethacrylates, methacrylate polymers, gelatin, agar, alginate, alginic acid, xanthan gum, hyaluronic acid, pectin, polysaccharides, carbomer, poloxamer, polyacrylamide, aluminium hydroxide, laponit, bentonit, polyoxyethylene- alkyl ether, polydextrose, polyethylene oxide or mixtures thereof.
9. The tablet according to claim 5 or 6, wherein lubricants are selected from the group comprising from magnesium stearate, colloidal silicon dioxide, calcium stearate, zinc stearate, waxes, boric acid, hydrogenated vegetable oil, sodium chlorate, magnesium lauryl sulfate, sodium oleate, sodium acetate, sodium benzoate, stearic acid, fatty acid, fumaric acid, glyceryl palmito sulphate, sodium stearyl fumarate, sodium lauryl sulphate or mixtures thereof.
10. The tablet according to claim 6, wherein disintegrants are selected from the group comprising croscarmellose sodium, low-substituted hydroxypropyl cellulose, pregelatinized starch, sodium carboxymethyl cellulose, calcium carboxymethyl cellulose, carboxymethyl cellulose, docusate sodium, guar gum, low substituted hydroxypropyl cellulose, polyacryline potassium, sodium alginate, corn starch, sodium starch glycolate, alginic acid, alginates, ion-exchange resins, magnesium aluminium silica, sodium dodesyl sulphate, poloxamer, sodium glycine carbonate, sodium lauryl sulphate or mixtures thereof.
11 . The tablet according to claim 6, wherein moisture absorbing agents are selected from the group comprising calcium chloride, calcium sulfate, activated carbon, zeolites, silica gel or mixtures thereof.
12. The tablet according to claim 5, wherein the mixture comprising metformin HCI also comprises at least one pharmaceutically acceptable excipient which are selected from the group comprising microcrystalline cellulose, sodium carboxymethyl cellulose, polyvinylpyrrolidone, magnesium stearate, pregelatinized starch, crospovidone or mixtures thereof.
13. The tablet according to claim 12, wherein the mixture comprising metformin HCI also comprising microcrystalline cellulose and polyvinylpyrrolidone.
14. The tablet according to claim 6, wherein the tablet comprising copovidone, microcrystalline cellulose, mannitol, magnesium stearate, talc, calcium chloride, croscarmellose sodium or mixtures thereof.
15. The tablet according to any preceding claim, wherein the tablet is obtained by using direct compression.
EP21829623.4A 2020-06-25 2021-05-07 A film coated tablet comprising vildagliptin and metformin hci Pending EP4171533A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TR2020/09949A TR202009949A1 (en) 2020-06-25 2020-06-25 A film coated tablet comprising vildagliptin and metformin hci
PCT/TR2021/050443 WO2021262116A1 (en) 2020-06-25 2021-05-07 A film coated tablet comprising vildagliptin and metformin hci

Publications (2)

Publication Number Publication Date
EP4171533A1 true EP4171533A1 (en) 2023-05-03
EP4171533A4 EP4171533A4 (en) 2024-07-17

Family

ID=79281618

Family Applications (1)

Application Number Title Priority Date Filing Date
EP21829623.4A Pending EP4171533A4 (en) 2020-06-25 2021-05-07 A film coated tablet comprising vildagliptin and metformin hci

Country Status (3)

Country Link
EP (1) EP4171533A4 (en)
TR (1) TR202009949A1 (en)
WO (1) WO2021262116A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022211762A1 (en) * 2021-03-29 2022-10-06 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi The film coated tablet of vildagliptin and metformin hydrochloride

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20180109A1 (en) * 2005-09-29 2019-01-30 Novartis Ag New Formulation
EP2295083A1 (en) * 2009-09-15 2011-03-16 Ratiopharm GmbH Pharmaceutical composition comprising active agents metformin and sitagliptin or vildagliptin
PT2938362T (en) * 2012-12-27 2017-03-06 Zentiva Saglik Ürünleri San Ve Tic A S Dry granulation process for producing tablet compositions of metformin and compositions thereof
EP3793529A1 (en) * 2018-05-18 2021-03-24 Galenicum Health S.L.U. Stable pharmaceutical compositions of dpp-iv inhibitors in combination with metformin in the form of immediate release tablets
GR1009644B (en) * 2018-09-25 2019-11-12 Φαρματεν Α.Β.Ε.Ε. Pharmaceutical composition comprising vildagliptin and metformin and method of preparation thereof

Also Published As

Publication number Publication date
TR202009949A1 (en) 2022-01-21
EP4171533A4 (en) 2024-07-17
WO2021262116A1 (en) 2021-12-30

Similar Documents

Publication Publication Date Title
CN110548026B (en) Pharmaceutical composition containing glucokinase activator and K-ATP channel blocker, and preparation method and application thereof
US8771735B2 (en) Immediate release dosage forms of sodium oxybate
EP2468268B1 (en) Combination composition of vildagliptin and gliclazide
WO2019203771A2 (en) Solid oral pharmaceutical compositions comprising sitagliptin
EP3731837A2 (en) The combination comprising linagliptin and metformin
WO2020242413A1 (en) A combination comprising alogliptin and metformin
KR101409330B1 (en) Sustained-Release combination preparations for the treatment of diabetes mellitus having enhanced compliance and preparation method thereof
US20150366863A1 (en) Solid oral pharmaceutical compositions comprising fixed dose combination of metformin and sitagliptin or salts thereof
EP4025194A1 (en) A combination comprising vildagliptin and metformin
EP4171533A1 (en) A film coated tablet comprising vildagliptin and metformin hci
US11813362B2 (en) Film-coated tablet comprising a triazine derivative for use in the treatment of diabetes
KR101497354B1 (en) Slow release pharmaceutical composition having Eperisone as active ingredient
WO2022119541A1 (en) A film coated tablet formulation comprising dapagliflozin and metformin hydrochloride
WO2018185669A1 (en) Effervescent compositions comprising saxagliptin or salt thereof
EP4161525A1 (en) The process for the preparation of a film coated tablet comprising linagliptin and metformin
US20150250734A1 (en) Stable pharmaceutical compositions of saxagliptin or salts thereof
WO2013115739A1 (en) Production method for formulations comprising comprising nateglinide and lipoic acid
EP4171532A1 (en) A stable combination of vildagliptin and metformin hci
WO2019132833A1 (en) The modified release combination comprising linagliptin and metformin
WO2014096983A1 (en) Stable pharmaceutical compositions of saxagliptin or salts thereof
WO2022035400A1 (en) A tablet formulation comprising sitagliptin and metformi̇n
WO2022211762A1 (en) The film coated tablet of vildagliptin and metformin hydrochloride
AU2019278014B2 (en) Pharmaceutical combination, composition and combination formulation containing glucokinase activator and K-ATP channel blocker, preparation method thereof and use thereof
WO2022173406A1 (en) A process for formulations of linagliptin or a pharmaceutically acceptable salt thereof
WO2022119540A2 (en) A process for formulations of dapagliflozin and metformin hydrochloride

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20221220

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230708

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Free format text: PREVIOUS MAIN CLASS: A61K0031155000

Ipc: A61K0009200000

A4 Supplementary search report drawn up and despatched

Effective date: 20240614

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/40 20060101ALI20240610BHEP

Ipc: A61K 31/155 20060101ALI20240610BHEP

Ipc: A61K 9/20 20060101AFI20240610BHEP